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Objectives: The aim of this study was to establish consensus for potential remission criteria 
for use in clinical trials of gout.  
Methods: Experts (n=88) in gout from multiple countries were invited to participate in a 
web-based questionnaire study. Three rounds of Delphi consensus exercises were conducted 
using SurveyMonkey® followed by a discrete choice experiment using 1000Minds®. The 
exercises focused on identifying domains, definitions for each domain and the timeframe 
over which remission should be defined.  
Results: There were 49 respondents (56% response) to the initial survey with subsequent 
response rates ranging from 57% to 90%. Consensus was reached for the inclusion of serum 
urate (98% agreement), flares (96%), tophi (92%), pain (83%) and patient global assessment 
(93%) of disease activity as measurement domains in remission criteria. Consensus was also 
reached for domain definitions including serum urate (< 0.36mM), pain (<2 on a 10-point 
scale) and patient global assessment (<2 on a 10-point scale), all of which should be 
measured at least twice over a set time interval. Consensus was not achieved in the Delphi 
exercise for the timeframe for remission with equal responses for six months (51%) and one 
year (49%).  In the discrete choice experiment, there was a preference towards 12 months as 
a timeframe for remission. 
Conclusion: These consensus exercises have identified domains and provisional definitions 
for gout remission criteria. Based on the results of these exercises, preliminary remission 
criteria are proposed with domains of serum urate, acute flares, tophus, pain and patient 
global assessment. These preliminary criteria now require testing in clinical datasets. 
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SIGNIFICANCE AND INNOVATIONS 
 
• There are currently no agreed upon remission criteria for gout. These consensus 
exercises have identified domains and provisional definitions for gout remission 
criteria. 
• Based on the results of these exercises, preliminary remission criteria are proposed 
with domains of serum urate, acute flares, tophus, pain and patient global assessment. 
Remission requires all of the criteria to be fulfilled. 
• There remains an important lack of consensus for the timeframe over which these 
domains should indicate absence of disease activity in order to define remission 
status. These preliminary criteria now require testing in clinical datasets and will be 
used as part of further consensus exercises to reach formal remission criteria for gout.  
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Gout is a chronic disease of monosodium urate crystal (MSU) deposition (1). Early disease is 
characterized by intermittent flares of an acute inflammatory arthritis. With uncontrolled 
hyperuricaemia, flares become more frequent and severe, with eventual development of 
tophi, joint damage and chronic gouty arthropathy. The cornerstone of effective gout 
management is long-term urate lowering therapy (ULT); over time, this therapy can lead to 
dissolution of MSU crystals, suppression of gout flares and regression of tophi (2-4).  
 
With the development of new ULT and anti-inflammatory agents for management of gout, 
the lack of validated outcome measures for clinical trials in gout became apparent (5). For 
more than a decade, the Outcomes in Rheumatology Clinical Trials (OMERACT) group have 
worked on the development of valid outcome measures for use in gout clinical trials. This 
work has led to endorsement of domains for both acute and chronic gout studies (and 
endorsement of instruments for most of the individual domains) (6-10).  However, it remains 
uncertain whether these individual domains can be usefully captured within a single outcome 
measure, either as a composite score or response criteria (11,12) 
 
Remission can be defined as the absence of signs and symptoms attributable to a disease, 
when the symptoms and signs can return in the future, with  the understanding that the 
momentary absence of signs and symptoms, particularly in conditions characterized by 
intermittent symptoms, does not equate to remission (13). With the availability of highly 
effective ULT, remission in gout should be possible and, indeed, a goal of therapy.  
Importantly, remission in gout should represent more than simply resolution of gout flare 
since the natural history of gout includes periods without symptoms and would not ordinarily 
be considered to represent periods of remission. To date, there are no remission criteria 
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established for gout (5). The importance of remission or inactive disease as a target has 
become well established in other rheumatic diseases such as rheumatoid arthritis (13).  
 
The aim of this study was to establish consensus for preliminary remission criteria for use in 




Eighty eight rheumatologists with an interest in gout from multiple countries were invited by 
email to participate in the study. The specialists were identified from previous studies in gout.  
Three rounds of a Delphi consensus exercise were conducted using SurveyMonkey® and a 
discrete choice experiment was completed using 1000Minds® (14,15). The exercises focused 
on identifying domains, definitions for each domain and the timeframe over which remission 
should be defined.  At the start of each survey, respondents were provided with the definition 
of remission (“the absence of signs and symptoms attributable to a disease, when the 
symptoms and signs can return in the future”) and instructed that the proposed remission 
criteria were primarily intended as an outcome measure for clinical trials (13).   
 
The Delphi exercises were conducted using a commercial online service (SurveyMonkey®). 
Questions focused on OMERACT-endorsed core domains for chronic gout studies, identified 
using qualitative methods including patient interviews and focus groups: serum urate, tophi, 
number of flares, pain and patient global assessment (6,9,10,16,17).  The respondents were 
asked to choose whether the domain was appropriate for inclusion in remission criteria in 
gout and to choose a timeframe which would need to be observed to define a state of 
remission (one week, one month, three months, six months or one year). Additionally they 
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were asked to give a preference about how measurements for serum urate, pain and patient 
global assessment would be reported; one measurement or multiple measurements.  For 
tophus assessment, respondents were asked whether regression in size or number or the 
absolute presence/absence of subcutaneous tophi would indicate remission. Consensus was 
defined as greater than 80% agreement in responses. For the first survey a single choice was 
required and in the subsequent surveys participants were asked to rank options. Options with 
less than 20% preference for first priority were discarded; all other options were included in 
the subsequent rounds of Delphi. Results of the previous survey were included in the 
questions as part of the Delphi process. Respondents were given approximately two weeks to 
respond to each survey. Surveys were repeated until consensus was reached or it became 
apparent that consensus would not be able to be reached.  Pain and patient global assessment 
questions were re-worded to provide clarity to respondents based on feedback provided in the 
surveys and to achieve consensus.  
 
Following the three rounds of Delphi exercises, a discrete choice experiment using 
1000Minds® was used to further explore the relative weightings for components of 
remission, in particular the timeframes of six and 12 months. 1000Minds® software uses a 
mathematical algorithm PAPRIKA (Potentially All Pairwise RanKings of all possible 
Alternatives) to construct relative weights for each remission domain from results of a series 
of pairwise comparisons of undominated pairs of all possible alternatives (a higher ranking 
category for one domain and a lower ranking category for the other domain) (15,18). Each 
question compares different timeframes of two indicators at a time and asks the respondent to 
choose the combination of indicators which he/she thought to be “more likely in remission”. 
Sufficient pairwise comparisons are made until the algorithm identifies a series of weights 
that are consistent with the decisions made. The relative weightings of timeframes for each 
Page 10 of 24
John Wiley & Sons, Inc.
Arthritis Care & Research












domain were assessed using a paired t-test.  Comparisons between the responders were 




There were 49 respondents in the first survey (56% response rate) and 73% were male. The 
mean age was 51.6 (SD 9.0) years, and duration in specialist rheumatology practice was 20.2 
(SD 10.4) years. Respondents resided in the following regions: Europe (36%), North America 
(29%), South America (8%), Asia (11%) and the Pacific (16%). Respondents reported seeing 
a mean of 34.4 (SD 34.0) patients with gout per month. Forty four responded to the second 
survey (90% of initial respondents) and 37 responded to the third survey (76% of initial 
respondents).  
 
Serum urate  
In the first survey, 98% of respondents agreed that serum urate measurement should be 
included as a domain in remission criteria. In the first survey, respondents were also asked to 
choose a timeframe over which serum urate would be assessed and how they would measure 
serum urate with: single value, averaged value or all values being below 0.36mM (6mg/dL). 
There was a preference (70% of respondents) for all values being below 0.36mM (6mg/dL).  
In the second survey respondents were asked about the timeframe and measurement of serum 
urate combined in order to help reach consensus.  Consensus was reached that serum urate 
measurements should be measured at least twice over a set time period and that all 
measurements should be below 0.36mM (6mg/dL) (94% agreement). The timeframe for 
measurement was not established after three Delphi rounds, with 58% choosing six months as 
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their first choice, 36% choosing one year and 6% choosing three months (Figure 1). There 
were no comments regarding lower serum urate levels for patients with tophaceous disease.  
 
Tophus 
In the first survey there was consensus for tophus as a domain with 92% choosing a form of 
tophus assessment. There was a spread of responses for tophus assessment with 47% 
choosing absence, 42% choosing regression in size or number and 4% choosing regression in 
size alone. In the second survey, there was no consensus reached on the definition of tophus 
response for remission, with 53% choosing absence, 43% choosing regression in size or 
number of tophi, and 4% reporting that tophus assessment was not useful.  
 
Flares 
In the first survey, 96% of respondents agreed that absence of acute flares should be included 
in remission criteria. However, after three Delphi rounds consensus was not reached on the 
timeframe over which absence of flares should be assessed, with one year preferred in 57%, 
six months in 40% and three months in 3% (Figure 1). 
 
Pain 
Questions focused on the measurement of pain generated a large amount of feedback in the 
first survey with the primary concern being potential difficulty distinguishing pain due to 
gout compared to pain due to other causes such as osteoarthritis. Additional concerns were 
the possibility of recall bias and the influence of acute attacks or chronic arthropathy on pain 
assessment. Therefore the second survey enquired specifically about whether “pain due to 
gout” should be included in remission criteria. In order to reduce recall bias the reporting of 
pain was also re-worded to state “in timeframe of a month or longer, two separate 
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measurements of pain would be averaged”.  Sixty percent chose to include pain in remission 
criteria in the second survey. During the second Delphi exercise, near consensus (77.7% 
choosing this option as their second or higher preference) was also reached that an average 
pain score of <2 on a 10-point pain scale was required for the remission definition. 
 
The question was repeated in the third survey with results and feedback from the second 
survey shown in accordance with Delphi methodology. In the final survey, consensus was 
reached with 83% agreement that “pain due to gout” should be included in remission criteria, 
using the average of two separate measurements over the timeframe at equal distance apart. 
Consensus was not reached for the actual timeframe of assessment of pain due to gout: in the 
final survey, 11% preferred one month, 14% three months, 29% six months and 46% one 
year (Figure 1).  
 
Patient Global Assessment  
In the first survey, 93% of respondents agreed that patient global assessment should be 
included in remission criteria. As with the pain domain, there was considerable feedback 
about the lack of specificity for gout and the potential for recall bias in patient global 
assessment. In response to these concerns, the patient global assessment measure was re-
worded in the second survey as a 10cm visual analogue scale or 10-point Likert scale with 
the question “considering all of the ways in which your gout affects you, how well have you 
been doing in the last week” (Very Well  1– Very Poorly 10).  The reporting was proposed to 
be two separate measurements over a time-frame at equal distance apart, with these 
measurements reported as an average. In the second survey, 84% agreed with this reporting 
of gout patient global assessment.  During the second Delphi exercise, near consensus 
(77.7%) was also reached that the patient global assessment of <2 on a 10-point pain scale 
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(i.e. 1 or less on Likert scale and <19mm on a 100mm VAS) was required for the remission 
definition.  Consensus was not reached for the timeframe of assessment of PGA: in the final 
survey, three months was preferred by 20%, six months by 37% and one year by 43% (Figure 
1).  
 
Timeframe of Remission 
In view of the substantial variation in timeframes for each of the domains, timeframes for 
overall remission was specifically explored in the final survey.  There was agreement that one 
week, one month and three months were not suitable timeframes for defining remission in 
gout.  However, after three surveys consensus was not reached regarding the timeframe, with 
six months (51%) and one year (49%) given approximately equal preference. 
 
1000Minds® Exercise 
In view of the lack of consensus from the initial Delphi exercise, a 1000Minds® exercise was 
used to explore the timeframe over which remission should be defined.  Participants who had 
completed all Delphi rounds were invited to participate in the 1000Minds® exercise. There 
were 21 respondents (57% response rate). Those who responded to the 1000Minds® exercise 
did not differ significantly from those did not respond to the 1000Minds® exercise; 
responders to the 1000Minds® exercise were 62% male, with mean age 50.1 years (P=0.15 
compared with non-responders), duration in specialist rheumatology was 18 years (P=0.09) 
and reported number of patients with gout seen a month 28.2 (P=0.98).  For all domains in 
this exercise, the 12 month period was preferred over six months (P<4x10
-6
) (Table 1). 
 
DISCUSSION 
These consensus exercises of multinational gout experts have identified domains and 
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provisional definitions for gout remission criteria. Based on the results of these exercises, 
preliminary remission criteria are proposed with domains of serum urate, acute flares, tophus, 
pain and patient global assessment (Table 2). Remission requires all of the criteria to be 
fulfilled.  
 
Although this exercise has identified domains and definitions for much of the remission 
criteria, there is an important lack of consensus concerning the timeframe over which these 
domains should indicate absence of disease activity in order to define remission status. A key 
issue for timeframe considerations is the trade-off between feasibility (being practically able 
to assess a domain over a long period of time e.g. 12 months) with validity (that patients with 
active disease may not flare for periods of several months or longer).  The 1000Minds® 
exercise showed a clear preference towards 12 months.  Due to the structural nature of the 
discrete choice experiments as implemented in 1000Minds®, 12 months would be expected 
to have the same or higher weighting compared to six months, but the finding that all 
domains show a highly significant preference to the longer duration has led to the provisional 
12 month timeframe. This issue will be addressed further through analysis of clinical trial 
data, to compare measures in the first and second six month periods of study participation.   
 
A limitation of the study is the relatively low response rate in the Delphi and 1000Minds® 
exercises. The initial response rate was 56% and 76% of those responded to the third survey. 
In the subsequent 1000Minds® exercise only 57% of those responding to the third survey 
participated, similar to that of comparable studies (16, 19). It is possible that inclusion of 
non-responders preferences may have altered the outcome of this study, but the 
characteristics of 1000Minds® non-responders did not differ significantly from those who 
completed all surveys. We also note that the proposed criteria are relatively tight and may 
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exclude some patients with chronic gouty arthropathy from achieving remission. It is 
recognized that patients with serum urate levels below 6mg/dL (or 5mg/dL if following ACR 
guidelines for patients with severe chronic tophaceous gouty arthropathy) with no flares, but 
with persistent tophi would not be defined as being in remission, according to the proposed 
criteria. Tophi, which are composed of chronic inflammatory tissue and urate crystals, are a 
cardinal feature of advanced gout and are recognized as a core domain for chronic gout 
studies by OMERACT (10, 20). Tophi are strongly associated with disability and there is 
face validity that patients with tophi are, by definition, not in remission (10, 21).  
 
Although there was strong agreement that tophus as a domain should be included in potential 
remission criteria there was uncertainly in how to assess this, with an even split of 
preferences for regression of tophus versus absence. In order to finalize provisional criteria, 
the strictest form of assessment (absence of tophus) was chosen.  Absence of tophus was 
preferred to tophus regression, as regression relates to a concept of change rather than the 
state of remission itself.  If absence was deemed to be too stringent, then the alternative 
would be a minimal tophus burden, which would require formal definition.  These definitions 
will be further tested in clinical trial datasets and used as part of further consensus exercises 
to reach formal remission criteria for gout.  
 
There was significant feedback on patients misattributing pain from other causes in scoring 
pain due to gout. Although there may be issues with feasibility with this domain being in 
proposed criteria, pain is a validated and OMERACT-endorsed patient reported outcome and 
therefore should be included in potential remission criteria (9).   
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These consensus exercises have identified domains and preliminary definitions for gout 
remission criteria, with a provisional timeframe for assessment of 12 months. These 
preliminary criteria now require testing for refinement and/or validation in clinical datasets.   
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Other respondents who contributed to some of the surveys: Lan Chen, Michael Doherty, N. 
Lawrence Edwards, Claudia Goldstein-Schainberg, Peter Gow, Tim Jansen, Vibeke Strand 
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Table 1.  Mean (SD) relative weightings of preference derived from the 1000Minds exercise, comparing 6 and 12 month time frames. P 
values refer to comparison between 6 and 12 months for each domain.  
 
Domain  Timeframe Mean (SD) weighting P  
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Table 2.  Proposed preliminary remission criteria for gout. All of the criteria must be achieved to meet the definition of remission.  
Domain Measurement 
Serum urate Serum urate < 0.36mM (6 mg/dl) at least twice over last 12 months
#
, and no values ≥ 0.36mM (6 mg/dl)^ 
Tophus None present 
Flares No flares during last 12 months  
Pain Pain due to gout < 2 at least twice over last 12 months
#
, and no values ≥ 2* 
Patient global assessment Patient global assessment of gout disease activity < 2 at least twice over last 12 months
#
, and no values ≥ 2* 
*using 10cm visual analogue scale or 10-point Likert-type scale 
# measurements at equal distances apart over the 12 months 
^ all intervening measurements must be below 0.36mM (6mg/dl) 
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Figure 1. Preferred timeframe for remission by domain from the third survey (percentage of 
respondents). PGA: patient global assessment.  
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Figure 1. Preferred timeframe for remission by domain from the third survey (percentage of respondents). 
PGA: patient global assessment.  
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